Meeting
2014 ASCO Annual Meeting
Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Authors
Mark Andrew Dickson
Memorial Sloan Kettering Cancer Center, New York, NY
Mark Andrew Dickson , Michelle R. Mahoney , William D. Tap , Sandra P. D'Angelo , Mary Louise Keohan , Brian Andrew Van Tine , Mark Agulnik , Laura E. Horvath , Gary K. Schwartz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT01653028
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10527)
DOI
10.1200/jco.2014.32.15_suppl.10527
Abstract #
10527
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma.
First Author: Mark Andrew Dickson
Poster
2016 Genitourinary Cancers Symposium
A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC).
First Author: Andrea Necchi
Poster
2011 ASCO Annual Meeting
A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST).
First Author: D. R. D'Adamo
Poster
2023 ASCO Annual Meeting
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
First Author: Sminu (Sam) Bose